New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 13, 2014
07:37 EDTENTAEnanta Pharmaceuticals reports Q1 EPS (30c), consensus (15c)
Reports Q1 revenue $893K, consensus $1.41M. The company said, "The changes in revenue for the three-month periods are primarily related to the timing and amount of milestone and other payments from collaborations, which have varied significantly from period to period and are expected to continue to do so."
News For ENTA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 23, 2015
16:06 EDTENTAEnanta reports Q4 EPS 29c, consensus 15c
Subscribe for More Information
15:28 EDTENTANotable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include Palo Alto (PANW), consensus 32c... Copart (CPRT), consensus 43c... Brocade (BRCD), consensus 24c... Post Holdings (POST), consensus 29c... YY (YY), consensus 82c... Dycom (DY), consensus $1.01... Cubic (CUB), consensus 96c... Enanta (ENTA), consensus 15c.
November 16, 2015
09:11 EDTENTAEnanta says ABT-493 study data show 'high sustained' response rates
Enanta Pharmaceuticals announced data from AbbVie's SURVEYOR studies of its investigational treatment regimen, consisting of ABT-493, an NS3/4A protease inhibitor, and ABT-530, an NS5A inhibitor, that show high rates of sustained virologic response at 12 weeks post-treatment in non-cirrhotic patients with chronic hepatitis C virus infection. After 12 weeks of treatment, SVR12 rates achieved were 97%-100% in genotype 1 patients, 96-100 percent in genotype 2, and 83%-94% in genotype 3. These data will be presented at The Liver Meeting, which is the Annual Meeting of the American Association for the Study of Liver Diseases in San Francisco. Separately, in a late-breaking presentation of the SURVEYOR-1 trial, additional data will show non-cirrhotic GT1 chronic HCV patients who received a shorter duration of treatment for 8 weeks with ABT-493 and ABT-530 achieved a SVR rate of 97%.
November 15, 2015
14:30 EDTENTAEnanta confirms interim Phase 3b data on Viekira Pak
Subscribe for More Information
November 13, 2015
08:28 EDTENTAAmerican Association for Study of Liver Diseases to hold annual meeting
The Liver Meeting 2015 is being held in San Francisco on November 13-17.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use